默沙东、 阿斯利康 中国区架构大调整:跨国药企在华两大销冠的重组、换血与转型。3月2日,默沙东中国宣布:整合药品业务、强化肿瘤事业部。几乎同一时间段,3月3日,阿斯利康中国也对外宣布:对肿瘤业务早期管线组织架构进行重大调整,设立两大跨领域管理集群。这是跨国药企曾经在华销售额排名第一、第二的两大巨头,接连对中国区的重要架构进行调整。这不是巧合。此前,诺和诺德业务重组、诺华重新整理整个县域团队、BMS...
Source Link默沙东、 阿斯利康 中国区架构大调整:跨国药企在华两大销冠的重组、换血与转型。3月2日,默沙东中国宣布:整合药品业务、强化肿瘤事业部。几乎同一时间段,3月3日,阿斯利康中国也对外宣布:对肿瘤业务早期管线组织架构进行重大调整,设立两大跨领域管理集群。这是跨国药企曾经在华销售额排名第一、第二的两大巨头,接连对中国区的重要架构进行调整。这不是巧合。此前,诺和诺德业务重组、诺华重新整理整个县域团队、BMS...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.